Filing Flows

Filing Flows › Companies › GeneDx Holdings › Cash flow

GeneDx Holdings cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$39.1M in Q2 2026 · −$75.8M over twelve months

Operating cash flow−$29.0M
Capital spending−$10.1M
Free cash flow−$39.1M
Cash conversion cycle81 days

Analysis

In Q2 2026, GeneDx Holdings generated −$29.0M of operating cash flow and spent $10.1M on capital projects, leaving free cash flow of −$39.1M. That is $47.1M less than in Q2 2025 ($8.1M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$48.7M; the largest uses were other financing ($55.1M), operating cash flow ($48.7M), capital spending ($27.1M); besides operations, cash came from net borrowing (+) / repaid (−) ($94.4M), shares issued ($34.2M); the cash balance fell by $13.8M.

Operating cash flow was −$29.0M against net income of −$17.7M. The largest differences: other operating capital −$10.9M, depreciation & amortization +$6.7M, receivables −$6.7M.

Its cash conversion cycle was 81 days (receivables 64 + inventory 38 − payables 21).

Free cash flow

GeneDx Holdings: free cash flow by quarterGeneDx Holdings: free cash flow by quarter−$5.0MQ3 2024−$6.2MQ4 2024$4.1MQ1 2025$8.1MQ2 2025$9.6MQ3 2025−$7.4MQ4 2025−$38.9MQ1 2026−$39.1MQ2 2026
Operating cash flow less capital spending.
GeneDx Holdings: operating cash flow against capital spendingGeneDx Holdings: operating cash flow against capital spendingOperating cash flowCapital spending−$4.4M$646KQ3 2024−$3.2M$3.0MQ4 2024$10.2M$6.1MQ1 2025$10.4M$2.4MQ2 2025$15.8M$6.2MQ3 2025−$3.1M$4.3MQ4 2025−$32.4M$6.5MQ1 2026−$29.0M$10.1MQ2 2026
Latest (Q2 2026): Operating cash flow −$29.0M, Capital spending $10.1M.

Capital allocation, year by year

GeneDx Holdings: where the cash came from (up) and went (down), by fiscal yearGeneDx Holdings: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsFY2021: Operating cash flow −$190MFY2021: Net borrowing −$3.7MFY2021: Shares issued $351MFY2021: Capital spending −$9.4M$351MFY2021FY2022: Operating cash flow −$319MFY2022: Net borrowing −$3.3MFY2022: Shares issued $201MFY2022: Capital spending −$7.2MFY2022: Acquisitions −$127M$201MFY2022FY2023: Operating cash flow −$180MFY2023: Net borrowing $45.0MFY2023: Shares issued $143MFY2023: Asset sales $4.0MFY2023: Capital spending −$5.2MFY2023: Acquisitions −$12.1M$192MFY2023FY2024: Operating cash flow −$28.5MFY2024: Net borrowing −$2.7MFY2024: Shares issued $46.9MFY2024: Capital spending −$5.5M$46.9MFY2024FY2025: Operating cash flow $33.3MFY2025: Shares issued $48.7MFY2025: Capital spending −$19.0M$82.0MFY2025
Over these 5 years operating cash flow totalled −$685M; the largest uses were operating cash flow ($718M) and acquisitions ($139M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$133M
Debt$100M
Net cash$32.5M
Due within a year$4.5M
Cash runway21 months

GeneDx Holdings is burning cash: its operations consume cash, a free cash flow of −$75.8M a year at the current rate against $133M of cash and investments: a runway of about 21 months; $4.5M of debt also comes due within a year, which the cash covers before any new financing.

GeneDx Holdings: debt maturities by year (FY2025)GeneDx Holdings: debt maturities by year (FY2025)$4.5MYear 1$50.0MYear 3
Principal due in each year as disclosed in the annual report, against $133M of cash and investments now.

Where the cash came from and went

GeneDx Holdings: sources (+) and uses (−) of cash, Q2 2026GeneDx Holdings: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$33.6MOperating cash flow−$29.0MCapital spending−$10.1MOther investing$4.5MOther financing$1.5MNet borrowing (+) / repaid (−)−$489K
GeneDx Holdings: sources (+) and uses (−) of cash, TTM to Q2 2026GeneDx Holdings: sources (+) and uses (−) of cash, TTM to Q2 2026Net borrowing (+) / repaid (−)$94.4MOther financing−$55.1MOperating cash flow−$48.7MShares issued$34.2MCapital spending−$27.1MCash drawn (+) / kept (−)$13.8MOther investing−$11.6M

From profit to cash

GeneDx Holdings: net income to operating cash flow, Q2 2026GeneDx Holdings: net income to operating cash flow, Q2 2026Net income−$17.7MDepreciation & amortization$6.7MStock-based pay$6.3MDeferred taxes−$518KReceivables−$6.7MInventory−$5.7MPayables$602KOther operating capital−$10.9MOperating cash flow−$29.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 202664382181
Q1 202667351883
Q4 20255131676
Q3 20254332966
Q2 202542352849
Q1 202543373742

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$29.0M−$10.1M−$489K—$33.6M−$39.1M
Q1 2026−$32.4M−$6.5M−$495K$534K$11.1M−$38.9M
Q4 2025−$3.1M−$4.3M−$377K$22.2M−$9.0M−$7.4M
Q3 2025$15.8M−$6.2M−$912K$12.0M−$21.8M$9.6M
Q2 2025$10.4M−$2.4M−$551K$65K$25.6M$8.1M
Q1 2025$10.2M−$6.1M−$611K$735K−$14.5M$4.1M
Q4 2024−$3.2M−$3.0M−$1.2M$32.1M−$27.3M−$6.2M
Q3 2024−$4.4M−$646K−$509K$14.7M−$1.8M−$5.0M

GeneDx Holdings: income statement and cash flow

GeneDx Holdings, Q2 2026: revenue $114M (+11% year over year), operating margin -15.3%. The chart follows the revenue to costs, profit and cash.

GeneDx Holdings: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.